4 weeks tomorrow it will have been 2 years since the request for Marketing Authorisation Application for DCVax was submitted to the @MHRAgovuk
Patients deserve better!
Beating brain cancer through vaccines and research
"Over a series of clinical trials, DCVax-L was shown to help extend the lives of people with newly diagnosed and recurrent glioblastoma — with some surviving far beyond the expected two-year expected survival for this diagnosis"
“There is a significant subgroup of patients who have lived more than five years,” Dr. Liau says.
"DCVax-L potentially represents one of the first successful brain cancer vaccines and a milestone in the field of cancer immunotherapy"
Dcvax -
First Phase 3 trial of a systematic treatment in 17 years to show a significant extension of mOS in nGBM
First Phase 3 trial of any type of treatment in 27 years to show a significant extention of mOS in rGBM
One of the first. if not the first. Phase 3 trial to show meaningful increases in the long-term tails of the survival curves in both nGBM and rGBM
Pristine safety profile
DCVax was the first ever medicine to be designated Promising Innovative Medicine (PIM) by MHRA
MHRA approved Northwest Biotherapeutic's Pediatric Investigation Plan (PIP) the external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company’s Phase III trial in adult patients.
Market Data 
Markets 
AI
